Efficacy of hepatitis B vaccine in susceptible spouses of chronic hepatitis B virus infected individuals at the time of marriage

Saudi Medical Journal

Volumn 28, Issue 4, 2007, Pages 540-543

  Roushan, Mohammad R ^a   Samie, Hayedeh ^a   Amiri, Mohammad J S ^a  

^a BABOL UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS B ANTIBODY; HEPATITIS B CORE ANTIBODY; HEPATITIS B SURFACE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; RECOMBINANT HEPATITIS B VACCINE;

ADULT; ANTIBODY BLOOD LEVEL; ANTIBODY DETECTION; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; INFECTION PREVENTION; INFECTION SENSITIVITY; IRAN; MAJOR CLINICAL STUDY; MALE; MARRIAGE; SPOUSE; VACCINATION; VIRUS TRANSMISSION;

ADULT; FEMALE; HEPATITIS B ANTIBODIES; HEPATITIS B VACCINES; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; IMMUNIZATION SCHEDULE; IRAN; MALE; MARRIAGE; SPOUSES; TREATMENT OUTCOME;

EID: 34447289988     PISSN: 03795284     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Mahoney FJ. Update on Diagnosis, Management, and Prevention of hepatitis B virus infection. Clin Microbiol Rev 1999; 12: 351-366.
2. Hoofnagle J. Chronic hepatitis B (editorial). N Engl J Med 1990; 323: 337-338.
3. Szmuness W, Stevens CE, Harley EJ, Zang EA, Oleszko WR, William DC, et al. Hepatitis B vaccine: Demonstration of efficacy in a controlled clinical trial in a high-risk population in the United States. N Engl J Med 1980; 303: 833-841.
4. Toukan A. Strategy for the control of hepatitis B virus infection in the Middle East and North Africa. The Middle East regional study group. Vaccine 1990; 8: S117-121.
5. Gimenez Sanchez F, Garcia Garcia F, Bernal Zamora MC, Ruiz Extremera A, Tomas Gilabert J, Salmon Escobar FJ. Intrafamilial contagion with the hepatitis B virus. Med Clin (Barc) 1991; 97: 170-174.
6. Thakur V, Guptan RC, Malhotra V, Basir SF, Sarin SK. Prevalence of hepatitis B infection within family contacts of chronic liver diseases patients. Does HBeAg positivity really matter? J Assoc Physicians India 2002; 50: 1386-1394.
7. Hou MC, Wu JC, Kuo BI, Sheng WY, Chen TZ, Lee SD, et al. Heterosexual transmission as the most common route of acute hepatitis B virus infection among adults in Taiwan. The importance of extending vaccination to susceptible adults. J Infect Dis 1993; 167:938-941.
8. Aoki H, Inaba N, Ohkawa R, Kudoh J, Takamizawa H.A study on the possible transmission of hepatitis B virus from HBsAg carrier women to their husbands. Acta Obstet Gynaecol Jpn 1981; 33: 767-776
9. Wiercinska-Drapalo A, Boron P, Boron-Kaczmarska A, Panasiuk A, Grzeszuk A, Flisiak R, et al. Epidemiology of intra-marital infections with hepatitis B virus (HBV) among the patients hospitalized in the infectious disease clinics in the Bialystok region 1988-1990. Przegl Epidemiol 1991; 45: 301-303.
10. Ko YC, Yen YY, Yeh SM, Lan SJ. Female to male transmission of hepatitis B virus between Chinese spouses. J Med Virol 1989; 27: 142-144.
11. Koziel MJ, Siddiqui A. Hepatitis B virus and hepatitis delta virus. In: Mandel GL, Bennett JE, Dolin R, editors. Principles and practice of infectious diseases, 6th ed. Philadelphia (PA): Churchill Livingstone; 2005. p. 1864-1890.
12. Poland GA, Jacobson RM. Prevention of hepatitis B with the hepatitis B vaccine. N Engl J Med 2004; 351: 2832-2838.
13. Harbour C, Farzadegan H, Sharma MK, Ala F. Professional and voluntary blood: A preliminary study in Iran. Vox sang 1978; 34: 87-91.
14. Farzadegan H, Shamszad M, Noori-Arya K. Epidemiology of viral hepatitis among Iranian population: A viral marker study. Ann Acad Med Singapore 1980; 9: 144-148.
15. Farzadegan H, Harbour C, Ala F. The prevalence of hepatitis B surface antigen and its antibody in blood donors and high-risk groups in Iran. Vox sang 1979; 37: 182-186.
16. Amini S, Mahmoodi MF, Andalibi S, Solati AA. Seroepidemiology of hepatitis B, delta and human immunodeficiency virus infections in Hamadan province, Iran: A population based study. J Trop Med Hyg 1993; 96: 277-287.
17. Farhat A, Khademi G, Mazouman SJ. The prevalence of hepatitis B carrier state in Khorassan province of Iran. Saudi Med J 2003; 24: 549-551.
18. Roumeliotou-Karayannis A, Papaevangelou G, Tassopoulos N, Richardson SC, Krugman S. Post-exposure active immunoprophylaxis of spouses of active viral hepatitis B patients. Vaccine 1985; 3: 31-34
19. Saltoglu N, Inal AS, Tasova Y, Kandemir O. Comparison of the accelerated and classic vaccination schedules against hepatitis B: Three-week hepatitis B vaccination schedule provides immediate and protective immunity. Ann Clin Microbiol Antimicrob 2003; 2: 10.
20. Marocho L, Vildozola H, Valencia E, Romero G, Huaman A, Solano L, et al. Comparative study on the protective effect of two immunization schemes using a hepatitis B recombinant vaccine in vulnerable health students. Rev Gastroenterol Peru 2005; 25: 313-319.
21. Harries AD, Clark M, Beeching NJ, Lavelle J, Mutton KJ. Early anti-HBs antibody response to accelerated and to conventional hepatitis B vaccination regimens in healthy persons. J Infect 1991; 23: 251-254.
22. Marsano LS, West DJ, Chan I, Hesley TM, Cox J, Hackworth V, et al. A two-dose hepatitis B vaccine regimen: Proof of priming and memory responses in young adults. Vaccine 1998; 16: 624-629.
23. Lemon SM, Thomas DL: Vaccines to prevent viral hepatitis. N Engl J Med 1997; 332: 196-204.
24. Orsolini P, Belloni C, Klersy C, Campisi D, Chirico G, Togni C, et al. Anti-HBV neonatal immunization with recombinant vaccine. Part I. Critical appraisal for a long-lived antibody course. Vaccine 1995; 13: 551-554.
25. Goldfarb J, Baley J, Medendorp SV, Seto D, Garcia H, Toy P, et al. Comparative study of the immunogenicity and safety of two dosing schedules of Engerix-B hepatitis B vaccine in neonates. Pediatr Infect Dis J 1994; 13: 18-22.
26. Clemens R, Sanger R, Kruppenbacher J, Hobel W, Stanbury W, Bock HL, et al. Booster immunization of low- and nonresponders after a standard three dose hepatitis B vaccine schedule--results of a post-marketing surveillance. Vaccine 1997; 15: 349-352.
27. Jacques P, Moens G, Desombere I, Dewijngaert J, Leroux-Roels G, Wettendorff M, et al. The immunogenicity and reactogenicity profile of a candidate hepatitis B vaccine in an adult vaccine non-responder population. Vaccine 2002; 20: 3644-3649.
28. Das K, Gupta RK, Kumar V, Kar P. Immunogenicity and reactogenicity of a recombinant hepatitis B vaccine in subjects over age of forty years and response of a booster dose among nonresponders. World J Gastroenterol 2003; 9: 1132-1134.
29. Perera J, Perera B, Gamage S. Seroconversion after hepatitis B vaccination in healthy young adults, and the effect of a booster dose. Ceylon Med J 2002; 47: 6-8.
30. Chiaramonte M, Ngatchu T, Maiori S, Baldo V, Moschen MF, Renzulli G, et al. Response to an extra dose of hepatitis B vaccine and specific antibody persistence in non-responders to primary immunization. Scand J Gastroenterol 1995; 30: 601-603.
31. Duval B, Boulianne N, De Serres G, De Wals P, Masse R, Trudeau G. Pre adolescent non-and hyporesponders following three doses of hepatitis B vaccine need only one more dose. Vaccine 2002; 20: 3632-3634.